BLAINJECTIONINJECTABLE
Approved
Sep 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
STELARA (ustekinumab) by Johnson & Johnson is interleukin-12 antagonists [moa]. Approved for psoriasis, crohn's disease, psoriatic arthritis and 1 more indications. First approved in 2009.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STELARA (ustekinumab) is a monoclonal antibody that antagonizes interleukin-12, a key cytokine in immune-mediated inflammatory diseases. It is approved for ten indications spanning dermatology, gastroenterology, and rheumatology, including psoriasis, Crohn's disease, psoriatic arthritis, ulcerative colitis, and atopic dermatitis. The drug works by blocking IL-12 signaling to reduce pathogenic T-cell responses.
LOE Approaching
As LOE approaches, the STELARA commercial team is likely transitioning from growth-focused activities to lifecycle management and cost-containment strategies.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications (4)
Worked on STELARA at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.